In one report, a patient with triple wild-type (BRAF/NRAS/NF1 WT) metastatic melanoma with two missense mutations in MAP2K1 showed a partial response to MEK inhibitor trametinib, followed by progression of disease after two months [45]. The gene discussed is NRAS; the disease is metastatic melanoma.